Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legal & IP

Set Alert for Legal & IP

Latest From Legal Issues

Judge Kavanaugh May Be Good US Supreme Court Pick For Pharma

Supreme Court nominee may side with biopharma companies in agency disputes, but it's unclear how he will rule on patent and product liability cases scheduled for review next term.

Legal Issues Intellectual Property

Liabilities Update: AbbVie Wins AndroGel Re-Trial; Actavis To Settle Out Of Testosterone MDL

For second time, judge finds problem with jury verdict against AbbVie; Bayer withdraws its appeal of Xarelto pre-trial rulings pending outcome of Supreme Court case.

BioPharmaceutical Policy

Nevada Price Transparency Regs Have Trade Secret Safeguards; Industry Drops Lawsuit

Regulations allow manufacturers to request that drug production and marketing costs and price contracting information provided to the state be kept confidential.

Pricing Debate Regulation

Opioid Litigation: Drug Mfrs. Lose Bid To Limit Data Disclosure; First Trials Set For March

US court orders firms to release information on all opioid products ever classified as Schedule II from one year prior to launch date; government, manufacturers oppose public disclosure of DEA distribution data.

Advertising, Marketing & Sales Legal Issues

FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal

Court finds AbbVie used sham litigation to maintain its monopoly on AndroGel but denies FTC request for an injunction; it is the largest monetary award in a litigated FTC antitrust case.

BioPharmaceutical Policy

US FDA’s Lowell Schiller Steps In As Acting Chief Counsel When Rebecca Wood Departs In July

A permanent successor to Wood, who will have held the agency's top legal post for only a year, will be announced in the near future, FDA Commissioner Gottlieb says; in the interim, Schiller, senior counsel to the commissioner and a former Senate HELP Committee staffer, will lead the chief counsel's office on an acting basis.


FDA Legal Issues
See All
UsernamePublicRestriction

Register